BioCryst Pharmaceuticals, Inc. (FRA:BO1)

Market Cap	1.37B -5.7%
Revenue (ttm)	511.22M +45.4%
Net Income	-7.48M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	13.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	233
Open	5.46
Previous Close	5.57
Day's Range	5.46 - 5.46
52-Week Range	5.46 - 9.90
Beta	n/a
RSI	37.88
Earnings Date	Feb 24, 2026

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1986
• Employees: 580
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BO1

Financial Performance

In 2024, BioCryst Pharmaceuticals's revenue was $450.71 million, an increase of 36.00% compared to the previous year's $331.41 million. Losses were -$88.88 million, -60.77% less than in 2023.

Financial numbers in USD